KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Invested Capital (2016 - 2025)

Historic Invested Capital for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $66.4 billion.

  • Eli Lilly's Invested Capital rose 5031.66% to $66.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $66.4 billion, marking a year-over-year increase of 5031.66%. This contributed to the annual value of $43.6 billion for FY2024, which is 4541.47% up from last year.
  • Per Eli Lilly's latest filing, its Invested Capital stood at $66.4 billion for Q3 2025, which was up 5031.66% from $54.2 billion recorded in Q2 2025.
  • Eli Lilly's 5-year Invested Capital high stood at $66.4 billion for Q3 2025, and its period low was $23.4 billion during Q2 2022.
  • Its 5-year average for Invested Capital is $34.6 billion, with a median of $30.0 billion in 2023.
  • As far as peak fluctuations go, Eli Lilly's Invested Capital crashed by 758.68% in 2022, and later skyrocketed by 5031.66% in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's Invested Capital stood at $25.9 billion in 2021, then dropped by 1.18% to $25.6 billion in 2022, then grew by 17.11% to $30.0 billion in 2023, then soared by 45.41% to $43.6 billion in 2024, then surged by 52.27% to $66.4 billion in 2025.
  • Its Invested Capital was $66.4 billion in Q3 2025, compared to $54.2 billion in Q2 2025 and $51.9 billion in Q1 2025.